Stock BPTH BIO-PATH HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
1.64 USD -8.38% Intraday chart for Bio-Path Holdings, Inc. -11.83% -82.29%
Jun. 14 Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress CI
Jun. 05 Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bio-Path Holdings Provides Clinical Update and Expansion Plans
AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress
CI
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding
CI
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
NE
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding
CI
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Top Midday Gainers
MT
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May
MT
Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session
MT
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At American Society of Clinical Oncology Annual Meeting
CI
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
AQ
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024
Bio-Path: Q1 Earnings Snapshot
AQ
Bio-Path Holdings Reports First Quarter 2024 Financial Results
AQ
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BPTH Stock
  4. News Bio-Path Holdings, Inc.